<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">100889084</journal-id><journal-id journal-id-type="nlm-ta">Diabetes Technol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Technol Ther</journal-id><journal-title-group><journal-title>Diabetes technology &#x00026; therapeutics</journal-title></journal-title-group><issn pub-type="ppub">1520-9156</issn><issn pub-type="epub">1557-8593</issn></journal-meta><article-meta><article-id pub-id-type="pmid">39146468</article-id><article-id pub-id-type="pmc">PMC7617696</article-id><article-id pub-id-type="manuscript">EMS205676</article-id><article-id pub-id-type="doi">10.1089/dia.2024.0298</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Safety of options to &#x02033;Boost&#x02033; (enhancing insulin infusion rates) and &#x02033;Ease-off&#x02033; (reducing insulin infusion rates) in CamAPS FX Hybrid Closed-Loop system: a real-world analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Royston</surname><given-names>Chlo&#x000eb;</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Bergford</surname><given-names>Simon</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Calhoun</surname><given-names>Peter</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sibayan</surname><given-names>Judy</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ruan</surname><given-names>Yue</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Boughton</surname><given-names>Charlotte</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Wilinska</surname><given-names>Malgorzata E</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hovorka</surname><given-names>Roman</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1">
<label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0264dxb48</institution-id><institution>Institute of Metabolic Science</institution></institution-wrap>-Metabolic Research Laboratories, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap>, <city>Cambridge</city>, <country country="GB">UK</country></aff><aff id="A2">
<label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ezjnq35</institution-id><institution>Jaeb Center for Health Research</institution></institution-wrap>, <city>Tampa</city>, <state>Florida</state>, <country country="US">USA</country></aff><aff id="A3">
<label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gh4er46</institution-id><institution>Shenzhen Institute of Advanced Technology</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>Chinese Academy of Sciences</institution></institution-wrap>, <city>Shenzhen</city>, <country country="CN">China</country></aff><author-notes><corresp id="CR1"><bold>Corresponding author:</bold> Roman Hovorka, PhD, Institute of Metabolic Science-Metabolic Research Laboratories,, University of Cambridge, Box 289, Addenbrooke&#x02019;s Hospital, Hills Road, Cambridge CB2 0QQ, UK. <email>rh347@cam.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><day>01</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>09</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>5</month><year>2025</year></pub-date><volume>27</volume><issue>1</issue><fpage>60</fpage><lpage>65</lpage><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">BY 4.0</ext-link> International license.</license-p></license></permissions><abstract><p id="P1">The usage and safety of the Boost and Ease-off features in the CamAPS FX hybrid closed-loop system was analysed in a retrospective analysis of real-world data from 7,464 users over a 12-month period. Boost was used more frequently than Ease-off, but for a shorter duration per use. Mean starting glucose was above range for Boost (229&#x000b1;51 mg/dL), and within range for Ease-off (114&#x000b1;29 mg/dL). Time spent below 70 mg/dL was low during Boost periods [median (IQR) 0.0% (0.0, 0.5%)], and lower than during no Boost periods [2.1% (1.2, 3.4%)], while time spent above 180 mg/dL was lower during Ease-off periods (15&#x000b1;14%) compared to no Ease-off periods (25&#x000b1;12%). There were no episodes of severe hypoglycaemia or DKA attributed to Boost or Ease-off use. Boost and Ease-off allow users to engage safely with CamAPS FX to manage their glucose levels during periods of more-than-usual and less-than-usual insulin needs.</p></abstract><kwd-group><kwd>Type 1 diabetes</kwd><kwd>hybrid closed-loop</kwd><kwd>CamAPS FX</kwd><kwd>Boost</kwd><kwd>Ease-off</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p id="P2">Hybrid closed-loop insulin delivery systems have become the standard of clinical care to manage type 1 diabetes (<xref rid="R1" ref-type="bibr">1</xref>). Hybrid closed-loop systems, through their glucose-responsive insulin delivery, improve glycaemic outcomes, increasing time in range without increasing the risk of hypoglycaemia in people with type 1 diabetes. (<xref rid="R2" ref-type="bibr">2</xref>)</p><p id="P3">The CamAPS FX hybrid closed-loop system comprising of the interoperable CamAPS FX app, a compatible continuous glucose monitor (CGM) and a compatible insulin pump, has been shown to be safe and effective in randomised clinical trials (<xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R6" ref-type="bibr">6</xref>), and in real-world analyses (<xref rid="R7" ref-type="bibr">7</xref>) across a wide range of ages (&#x02265;2 years old) including during pregnancy. Boost and Ease-off are unique features of the CamAPS FX app, which allow enhanced customisability for users, so that the risk of hypoglycaemia can be reduced during periods of increased insulin sensitivity such as exercise (Ease-off), and glucose control can be improved when insulin sensitivity is lower such as during intercurrent illness, stress or hormonal changes associated with menstrual cycles or puberty (Boost). (<xref rid="R8" ref-type="bibr">8</xref>)</p><p id="P4">It is important to evaluate the safety and usage of the Boost and Ease-off features to ensure that these features are utilised appropriately, Boost does not increase the risk of hypoglycaemia, and Ease-off does not increase the risk of hyperglycaemia. The objective of the present study was to analyse the usage and safety of Boost and Ease-off across all age groups using real-world data.</p></sec><sec sec-type="materials | methods" id="S2"><title>Materials and methods</title><sec id="S3"><title>Study design and study population</title><p id="P5">Twelve months of real-world data collected between 1 December 2022 and 30 November 2023 was retrospectively analysed. Users aged between 1 and 80 years old using CamAPS FX (control algorithm version 0.3.71; CamDiab, Cambridge, UK), Dexcom G6 (Dexcom, CA, USA) and YpsoPump (Ypsomed, Burgdorf, Switzerland), and who provided consent to share their data were included. Data were analysed for individuals who used closed-loop for a minimum of 8 weeks. The data-set includes users with varying duration of use of CamAPS FX.</p></sec><sec id="S4"><title>CamAPS FX closed-loop system</title><p id="P6">CamAPS FX is an interoperable hybrid closed-loop app compatible with the Dexcom G6 and FreeStyle Libre 3 (Abbott Diabetes Care, Alameda, CA, USA) continuous glucose monitors, and the YpsoPump, DANA Diabecare RS and DANA-I insulin pumps (Sooil, Seoul, Republic of Korea). The app, installed on a standard Android smartphone, uses an adaptive model predictive control algorithm for titrating insulin delivery. (<xref rid="R9" ref-type="bibr">9</xref>) The algorithm is initialised by entering the user&#x02019;s weight and total daily insulin dose. Insulin sensitivity and active insulin time are automatically calculated and adjusted by the algorithm as necessary. The control algorithm is highly adaptive by adjusting total daily insulin requirements, diurnal variations, and insulin delivery around meals. The default glucose target is 104 mg/dL but this can be adjusted between 80 mg/dL and 200 mg/dL in segments of 30 minutes (<xref rid="R10" ref-type="bibr">10</xref>).</p><p id="P7">The CamAPS FX app has two features, Boost and Ease-off, providing enhanced customisability to the users at times of higher or lower insulin needs, respectively. During Boost use, the control algorithm increases the amount of insulin delivered by assuming higher insulin needs corresponding to approximately a 35% increase of the total daily dose (TDD) in a glucose-responsive manner; there is no change in glucose target. During Ease-off, the glucose target and insulin sensitivity are increased causing the control algorithm to deliver less insulin.</p><p id="P8">Users are advised that Boost can be used when insulin requirements are higher (e.g., during illness, growth surges, certain times of the menstrual cycle or times of unusual hyperglycaemia), while Ease-off can be used during periods when less insulin is needed and/or insulin sensitivity is higher (e.g., during exercise or times of increased hypoglycaemia risk). (<xref rid="R11" ref-type="bibr">11</xref>)</p></sec><sec id="S5"><title>Data analysis</title><p id="P9">Each sensor glucose reading was determined to be either in Boost mode, Ease-off mode, or neither mode. Glucose endpoints were calculated for each mode if the participant had &#x02265;4 hours in the respective mode. Only data from periods with closed-loop mode on were included. All endpoints were calculated per participant giving equal weight to each user.</p><p id="P10">Analyses were conducted across all users, and across six pre-defined age groups: 1-6 years, 7-13 years, 14-17 years, 18-22 years, 23-65 years and &#x02265;66 years old. Mean sensor glucose, time spent in range 70-180 mg/dL, time below 70 mg/dL, below 54 mg/dL, above 180 mg/dL and above 250 mg/dL were calculated for each population. Mean duration, frequency of use (number of times per week), and mean glucose on initialisation of each feature was calculated for periods when Boost was on and when Ease-off was on. Percentage of time with sensor glucose availability and closed-loop use while features were in use was also calculated. Episodes of severe hypoglycaemia or diabetic ketoacidosis (DKA) were collected through the post-market surveillance process which includes a wide range of data from multiple sources, from all 15 countries where CamAPS FX is available. Relevant data was inspected to determine whether Boost or Ease-off were used prior to or during these events.</p><p id="P11">Data analysis was completed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA). Data is presented as mean &#x000b1; standard deviation for normally distributed data or median (interquartile range) for non-normally distributed data.</p></sec></sec><sec sec-type="results" id="S6"><title>Results</title><p id="P12">A total of 7,464 users who met the inclusion criteria were included in the analysis. Mean age was 32&#x000b1;19 years. A median of 89 (58, 119) days of sensor glucose data per user was analysed. The median percentage of time with sensor glucose and closed-loop on while Boost or Ease-off were in use was 97% (93, 99%) and was consistent across all age groups between 95 and 98% (<xref rid="T1" ref-type="table">Table 1</xref>).</p><sec id="S7"><title>Boost and Ease-off usage</title><p id="P13">Endpoints stratified by age group are provided in <xref rid="T1" ref-type="table">Table 1</xref> and 2. Boost was used more frequently than Ease-off at median 4.3 (1.8, 8.6) times per week compared to 2.4 (1.0, 5.4) times per week, but for a shorter duration of 65 (43, 98) minutes for Boost compared to 82 (56, 120) minutes for Ease-off (<xref rid="F1" ref-type="fig">Figure 1</xref>). Boost was used the most frequently in very young children (1-6 years old) at 6.2 (3.1, 11.5) times per week, while young adults (18-22 years old) used it the least often at only 3.6 (1.4, 8.0) times per week. The duration of Boost was shortest for very young children at 47 (31, 68) minutes and longest for young adults at 77 (51, 112) minutes (<xref rid="T1" ref-type="table">Table 1</xref>). Similar patterns were observed with Ease-off, with its use most frequent in very young children at 3.2 (1.4, 8.5) times per week but for the shortest duration of 64 (42, 99) minutes. Young adults had the longest duration of Ease-off use at 98 (62, 143) minutes while teenagers (14-17 years old) used Ease-off the least often at a median of 1.9 (0.9, 4.2) times per week (Table 2). The frequency of use of Boost and Ease-off over the 24 hour period by age group (&#x0003c;18 years and &#x02265;18 years) is shown in the <xref rid="SD1" ref-type="supplementary-material">Supplementary Appendix (Figure S1)</xref>. The duration of Boost and Ease-off use by month for those participants starting closed-loop during the data collection period was sustained over time (<xref rid="SD1" ref-type="supplementary-material">Table S2</xref>).</p></sec><sec id="S8"><title>Sensor glucose endpoints</title><p id="P14">Time in range (70-180 mg/dL), above (&#x0003e;180 mg/dL) and below (&#x0003c;70 mg/dL) range are shown for periods when Boost was on versus off and when Ease-off was on versus off in <xref rid="T1" ref-type="table">Table 1</xref> and 2. Mean glucose on initiating Boost was 229&#x000b1;51 mg/dL. There was very little time in hypoglycaemia during Boost periods; median time below 70 mg/dL was 0.0% (0.0, 0.5%) and time below 54 mg/dL was 0.0% (0.0, 0.0%) (Figure 2). During Boost, time in range was 28&#x000b1;22%, mean sensor glucose was 228&#x000b1;46 mg/dL, and time above range was 72&#x000b1;22%. Sensor glucose when Ease-off was initiated was 114&#x000b1;29 mg/dL. Time in range during Ease-off periods was 75&#x000b1;14%, mean sensor glucose was 127&#x000b1;27 mg/dL (Table 2), and time above 180 mg/dL was 15&#x000b1;14% (Figure 2). Median time above 250 mg/dL was low at 1.0% (0.0, 4.0%). Time below 70 mg/dL was 7.0% (2.9, 14.4%). In keeping with overall glycaemic trends in this age cohort, very young children had the highest time below range during Ease-off periods at 9.9% (3.6, 18.8%) (Table 2).</p><p id="P15">When neither Boost nor Ease-off feature was on, time in range was 73&#x000b1;12%, time below range was 2.1% (1.2, 3.4%), time above range was 25&#x000b1;12% and mean sensor glucose was 151&#x000b1;20 mg/dL.</p><p id="P16">Trends in glycaemic metrics by age categories were similar during Boost on, Ease-off on and when neither Boost nor Ease-off were on, with older adults (&#x02265;66 years old) having the lowest mean sensor glucose, highest time in range and lowest time above range, with minimal time below range. Very young children had lowest time in range, highest time above range and relatively high time below 70 mg/dL (<xref rid="T1" ref-type="table">Table 1</xref> and Table 2).</p></sec><sec id="S9"><title>Boost and Ease-off usage and serious adverse events</title><p id="P17">One severe hypoglycaemia event occurred when Boost was on, however this occurred when Boost was initiated shortly after a manual bolus overcorrection. One DKA episode occurred when Ease-off was on which was attributed to an infusion set failure.</p></sec></sec><sec sec-type="discussion" id="S10"><title>Discussion</title><p id="P18">Our analysis shows that Boost and Ease-off are frequently used features of the CamAPS FX hybrid closed-loop app,suggesting acceptability, ease-of-use, and a desire for some engagement with the system by the user. While other commercially available hybrid closed-loop systems usually have a feature that directs the system to target higher glucose values or reduce insulin delivery (e.g. activity mode) (<xref rid="R12" ref-type="bibr">12</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref>), none of the other systems have a function such as Boost, which increases insulin delivery to deal with periods of increased insulin resistance or insulin requirements. Our analysis shows that Boost was used more frequently than Ease-off across all age groups.</p><p id="P19">Caregivers of very young children, aged 1-6 years used the two features the most frequently. This likely reflects the unique challenges faced by this population including unpredictable activity, erratic meal consumption and intense management required to mitigate these challenges (<xref rid="R15" ref-type="bibr">15</xref>). Young adults aged 18-22 years tended to use these features less frequently which may reflect their reduced overall engagement with the app and diabetes management (<xref rid="R15" ref-type="bibr">15</xref>). This age group often struggles to meet recommended glycaemic targets due to the additional challenges and competing priorities of young adulthood such as moving away from home support systems, and starting higher education or work (<xref rid="R16" ref-type="bibr">16</xref>).</p><p id="P20">Boost appears to have been used for its intended purpose with a mean starting glucose of 229 mg/dL when Boost is turned on. Consequently, time in range during Boost periods was lower due to higher time spent in hyperglycaemia and higher starting glucose. Importantly from a safety perspective, time below 70 mg/dL and 54 mg/dL were very low during Boost use overall with median 0.0%, including in very young children and older adults where the risks and consequences of hypoglycaemia are greatest. Our results are similar to those observed in a previous analysis of Boost using data from clinical trials (<xref rid="R17" ref-type="bibr">17</xref>).</p><p id="P21">Ease-off was initiated when glucose was within target range with mean starting glucose 114 mg/dL, suggesting that users may be using Ease-off proactively, prior to becoming hypoglycaemic, while Boost is used in a more reactive way once users are already experiencing hyperglycaemia. As would be expected for a feature designed to be used during periods of increased insulin sensitivity, time spent below 70 mg/dL was higher during Ease-off periods than when Ease-off was not used (median 7.0% vs. 2.1%). Importantly, the reduced insulin delivery during Ease-off did not lead to significant hyperglycaemia, as the mean time above 180 mg/dL was 15% and the median time above 250 mg/dL was 1%.</p><p id="P22">Strengths of the present study include the wide range of ages included (between 1 and 80 years), the use of real-world data, and the frequent use of Boost and Ease-off across all age groups allowing evaluation of its safety in the most vulnerable age groups, including very young and elderly. Limitations include the retrospective nature of the analyses which does not allow us to understand the reason why users initiated Boost/Ease-off or provide a comparator of glucose outcomes if Boost/Ease-off were not intiiated, and the fact that the only demographic data available was the year of birth.</p><p id="P23">In conclusion, user-initiated closed-loop features Boost and Ease-off are safe. These features are frequently used by users across all age groups and most frequently by caregivers of young children. Boost and Ease-off allow users to engage safely with CamAPS FX to manage their glucose levels at periods of more-than-usual and less-than-usual insulin needs.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>Supplementary Appendix</label><media xlink:href="EMS205676-supplement-Supplementary_Appendix.pdf" id="d67e322" position="anchor"/></supplementary-material></sec></body><back><ack id="S11"><title>Funding and Assistance</title><p>Support is acknowledged for the artificial pancreas work at the University of Cambridge from National Institute for Health Research Cambridge Biomedical Research Centre. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.</p></ack><fn-group><fn fn-type="con" id="FN1"><p id="P24">
<bold>Author Contributions</bold>
</p><p id="P25">SB, PC, CKB, MEW and RH co-designed the analysis. CR, SB, PC, YR, CB, MEW, and RH carried out or supported data analysis, including statistical analysis. CR wrote the manuscript. RH designed the control algorithm. All authors critically reviewed the manuscript.</p></fn><fn fn-type="COI-statement" id="FN2"><p id="P26">
<bold>Conflict of Interest</bold>
</p><p id="P27">YR is a consultant at CamDiab. CKB is a consultant at CamDiab and has received speaker honoraria from Ypsomed. MEW is a consultant at CamDiab and reports patents related to closed-loop. RH reports having received speaker honoraria from Eli Lilly, Dexcom, and Novo Nordisk, receiving license fees from BBraun; patents related to closed-loop, being consultant to Abbott Diabetes Care, and being director at CamDiab. CR, SB, PC and JS report no conflicts of interest related to the present paper.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phillip</surname><given-names>M</given-names></name>
<name><surname>Nimri</surname><given-names>R</given-names></name>
<name><surname>Bergenstal</surname><given-names>RM</given-names></name>
<name><surname>Barnard-Kelly</surname><given-names>K</given-names></name>
<name><surname>Danne</surname><given-names>T</given-names></name>
<name><surname>Hovorka</surname><given-names>R</given-names></name>
<etal/>
</person-group><article-title>Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice</article-title><source>Endocr Rev</source><year>2023</year><month>Mar</month><day>4</day><volume>44</volume><issue>2</issue><fpage>254</fpage><lpage>80</lpage><!--<pub-id pub-id-type="pmcid">PMC9985411</pub-id>--><pub-id pub-id-type="doi">10.1210/endrev/bnac022</pub-id><pub-id pub-id-type="pmid">36066457</pub-id>
</element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiao</surname><given-names>X</given-names></name>
<name><surname>Shen</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
</person-group><article-title>Better TIR, HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis</article-title><source>BMJ Open Diabetes Res Care</source><year>2022</year><month>Apr</month><volume>10</volume><issue>2</issue><elocation-id>e002633</elocation-id><!--<pub-id pub-id-type="pmcid">PMC9024214</pub-id>--><pub-id pub-id-type="doi">10.1136/bmjdrc-2021-002633</pub-id><pub-id pub-id-type="pmid">35450868</pub-id>
</element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ware</surname><given-names>J</given-names></name>
<name><surname>Allen</surname><given-names>JM</given-names></name>
<name><surname>Boughton</surname><given-names>CK</given-names></name>
<name><surname>Wilinska</surname><given-names>ME</given-names></name>
<name><surname>Hartnell</surname><given-names>S</given-names></name>
<name><surname>Thankamony</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes</article-title><source>N Engl J Med</source><year>2022</year><month>Jan</month><day>20</day><volume>386</volume><issue>3</issue><fpage>209</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">35045227</pub-id>
</element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boughton</surname><given-names>CK</given-names></name>
<name><surname>Hartnell</surname><given-names>S</given-names></name>
<name><surname>Thabit</surname><given-names>H</given-names></name>
<name><surname>Mubita</surname><given-names>WM</given-names></name>
<name><surname>Draxlbauer</surname><given-names>K</given-names></name>
<name><surname>Poettler</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study</article-title><source>Lancet Healthy Longev</source><year>2022</year><month>Mar</month><volume>3</volume><issue>3</issue><fpage>e135</fpage><lpage>42</lpage><!--<pub-id pub-id-type="pmcid">PMC8967297</pub-id>--><pub-id pub-id-type="doi">10.1016/S2666-7568(22)00005-8</pub-id><pub-id pub-id-type="pmid">35359882</pub-id>
</element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>TTM</given-names></name>
<name><surname>Collett</surname><given-names>C</given-names></name>
<name><surname>Bergford</surname><given-names>S</given-names></name>
<name><surname>Hartnell</surname><given-names>S</given-names></name>
<name><surname>Scott</surname><given-names>EM</given-names></name>
<name><surname>Lindsay</surname><given-names>RS</given-names></name>
<etal/>
</person-group><article-title>Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes</article-title><source>N Engl J Med</source><year>2023</year><month>Oct</month><day>26</day><volume>389</volume><issue>17</issue><fpage>1566</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">37796241</pub-id>
</element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boughton</surname><given-names>CK</given-names></name>
<name><surname>Allen</surname><given-names>JM</given-names></name>
<name><surname>Ware</surname><given-names>J</given-names></name>
<name><surname>Wilinska</surname><given-names>ME</given-names></name>
<name><surname>Hartnell</surname><given-names>S</given-names></name>
<name><surname>Thankamony</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes</article-title><source>N Engl J Med</source><year>2022</year><month>Sep</month><day>8</day><volume>387</volume><issue>10</issue><fpage>882</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">36069870</pub-id>
</element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alwan</surname><given-names>H</given-names></name>
<name><surname>Wilinska</surname><given-names>ME</given-names></name>
<name><surname>Ruan</surname><given-names>Y</given-names></name>
<name><surname>Da Silva</surname><given-names>J</given-names></name>
<name><surname>Hovorka</surname><given-names>R</given-names></name>
</person-group><article-title>Real-World Evidence Analysis of a Hybrid Closed-Loop System</article-title><source>J Diabetes Sci Technol</source><year>2023</year><month>Jul</month><day>8</day><elocation-id>19322968231185348</elocation-id><!--<pub-id pub-id-type="pmcid">PMC11873883</pub-id>--><pub-id pub-id-type="doi">10.1177/19322968231185348</pub-id><pub-id pub-id-type="pmid">37421250</pub-id>
</element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boughton</surname><given-names>CK</given-names></name>
<name><surname>Hovorka</surname><given-names>R</given-names></name>
</person-group><article-title>New closed-loop insulin systems</article-title><source>Diabetologia</source><year>2021</year><month>May</month><volume>64</volume><issue>5</issue><fpage>1007</fpage><lpage>15</lpage><!--<pub-id pub-id-type="pmcid">PMC8012332</pub-id>--><pub-id pub-id-type="doi">10.1007/s00125-021-05391-w</pub-id><pub-id pub-id-type="pmid">33550442</pub-id>
</element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ware</surname><given-names>J</given-names></name>
<name><surname>Allen</surname><given-names>JM</given-names></name>
<name><surname>Boughton</surname><given-names>CK</given-names></name>
<name><surname>Wilinska</surname><given-names>ME</given-names></name>
<name><surname>Hartnell</surname><given-names>S</given-names></name>
<name><surname>Thankamony</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes</article-title><source>N Engl J Med</source><year>2022</year><month>Jan</month><day>20</day><volume>386</volume><issue>3</issue><fpage>209</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">35045227</pub-id>
</element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuchs</surname><given-names>J</given-names></name>
<name><surname>Hovorka</surname><given-names>R</given-names></name>
</person-group><article-title>Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy</article-title><source>Expert Rev Med Devices</source><year>2020</year><month>Jul</month><day>2</day><volume>17</volume><issue>7</issue><fpage>707</fpage><lpage>20</lpage><!--<pub-id pub-id-type="pmcid">PMC7441745</pub-id>--><pub-id pub-id-type="doi">10.1080/17434440.2020.1784724</pub-id><pub-id pub-id-type="pmid">32569476</pub-id>
</element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nwokolo</surname><given-names>M</given-names></name>
<name><surname>Hovorka</surname><given-names>R</given-names></name>
</person-group><article-title>The Artificial Pancreas and Type 1 Diabetes</article-title><source>J Clin Endocrinol Metab</source><year>2023</year><month>Jun</month><day>16</day><volume>108</volume><issue>7</issue><fpage>1614</fpage><lpage>23</lpage><!--<pub-id pub-id-type="pmcid">PMC10271231</pub-id>--><pub-id pub-id-type="doi">10.1210/clinem/dgad068</pub-id><pub-id pub-id-type="pmid">36734145</pub-id>
</element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="webpage"><collab>Setting Temp Target &#x02212; MiniMed&#x02122; 780G System Support | Medtronic</collab><year>2023</year><date-in-citation>cited 2024 Apr 17</date-in-citation><comment>[Internet] Available from: <ext-link xlink:href="https://www.medtronicdiabetes.com/customer-support/minimed-780g-system-support/setting-temp-target" ext-link-type="uri">https://www.medtronicdiabetes.com/customer-support/minimed-780g-system-support/setting-temp-target</ext-link></comment></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="webpage"><collab>Omnipod&#x000ae; 5 Training Series - Activity Feature | Omnipod</collab><date-in-citation>cited 2024 Apr 17</date-in-citation><comment>[Internet] Available from: <ext-link xlink:href="https://www.omnipod.com/current-podders/resources/omnipod-5/videos/activity-feature" ext-link-type="uri">https://www.omnipod.com/current-podders/resources/omnipod-5/videos/activity-feature</ext-link></comment></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="webpage"><collab>Support</collab><source>Exercise Activity</source><date-in-citation>cited 2024 Apr 17</date-in-citation><comment>[Internet] Available from: <ext-link xlink:href="https://support.tandemdiabetes.com/hc/en-us/articles/1500011430822-Exercise-Activity" ext-link-type="uri">https://support.tandemdiabetes.com/hc/en-us/articles/1500011430822-Exercise-Activity</ext-link></comment></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dovc</surname><given-names>K</given-names></name>
<name><surname>Boughton</surname><given-names>C</given-names></name>
<name><surname>Tauschmann</surname><given-names>M</given-names></name>
<name><surname>Thabit</surname><given-names>H</given-names></name>
<name><surname>Bally</surname><given-names>L</given-names></name>
<name><surname>Allen</surname><given-names>JM</given-names></name>
<etal/>
</person-group><article-title>Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery</article-title><source>Diabetes Care</source><year>2019</year><month>Jul</month><day>1</day><volume>42</volume><issue>7</issue><fpage>1344</fpage><lpage>7</lpage><!--<pub-id pub-id-type="pmcid">PMC6609966</pub-id>--><pub-id pub-id-type="doi">10.2337/dc18-2625</pub-id><pub-id pub-id-type="pmid">31221700</pub-id>
</element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morrissey</surname><given-names>EC</given-names></name>
<name><surname>Dinneen</surname><given-names>SF</given-names></name>
<name><surname>Lowry</surname><given-names>M</given-names></name>
<name><surname>De Koning</surname><given-names>EJ</given-names></name>
<name><surname>Kunneman</surname><given-names>M</given-names></name>
</person-group><article-title>Reimagining care for young adults living with type 1 diabetes</article-title><source>J Diabetes Investig</source><year>2022</year><month>Aug</month><volume>13</volume><issue>8</issue><fpage>1294</fpage><lpage>9</lpage><!--<pub-id pub-id-type="pmcid">PMC9340877</pub-id>--><pub-id pub-id-type="doi">10.1111/jdi.13824</pub-id><pub-id pub-id-type="pmid">35511075</pub-id>
</element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ware</surname><given-names>J</given-names></name>
<name><surname>Wilinska</surname><given-names>ME</given-names></name>
<name><surname>Ruan</surname><given-names>Y</given-names></name>
<name><surname>Allen</surname><given-names>JM</given-names></name>
<name><surname>Boughton</surname><given-names>CK</given-names></name>
<name><surname>Hartnell</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Safety of User-Initiated Intensification of Insulin Delivery Using Cambridge Hybrid Closed-Loop Algorithm</article-title><source>J Diabetes Sci Technol</source><year>2022</year><month>Dec</month><day>8</day><elocation-id>193229682211419</elocation-id><!--<pub-id pub-id-type="pmcid">PMC11307210</pub-id>--><pub-id pub-id-type="doi">10.1177/19322968221141924</pub-id><pub-id pub-id-type="pmid">36475908</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1</label><caption><p>(a) Frequency of Boost and Ease-off use (b) Duration of each Boost and Ease-off period (c) Percentage of time below range when Boost is on compared to Boost off (d) Percentage of time above range when Ease-off is on compared to Ease-off off.</p></caption><graphic xlink:href="EMS205676-f001" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><title>Sensor glucose outcomes during Boost, Ease-off and neither periods using real-world data.</title></caption><table frame="box" rules="cols"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">All users</th><th valign="middle" align="center" rowspan="1" colspan="1">Young children Age 1 &#x02212; 6 years</th><th valign="middle" align="center" rowspan="1" colspan="1">Pre-pubertal Children Age 7 &#x02212; 13 years</th><th valign="middle" align="center" rowspan="1" colspan="1">Teenagers Age 14 &#x02212; 17 years</th><th valign="middle" align="center" rowspan="1" colspan="1">Young adults Age 18 &#x02212; 22 years</th><th valign="middle" align="center" rowspan="1" colspan="1">Adults Age 23 &#x02212; 65 years</th><th valign="middle" align="center" rowspan="1" colspan="1">Older Adults Age 66 years and older</th></tr></thead><tbody><tr style="border-bottom: solid thin"><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Number of participants</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">7464</td><td valign="top" align="center" rowspan="1" colspan="1">705</td><td valign="top" align="center" rowspan="1" colspan="1">991</td><td valign="top" align="center" rowspan="1" colspan="1">515</td><td valign="top" align="center" rowspan="1" colspan="1">421</td><td valign="top" align="center" rowspan="1" colspan="1">4590</td><td valign="top" align="center" rowspan="1" colspan="1">242</td></tr><tr style="border-bottom: solid thin"><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age</bold> (years)</td><td valign="top" align="center" rowspan="1" colspan="1">32 &#x000b1; 19</td><td valign="top" align="center" rowspan="1" colspan="1">5 &#x000b1; 1</td><td valign="top" align="center" rowspan="1" colspan="1">10 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">15 &#x000b1; 1</td><td valign="top" align="center" rowspan="1" colspan="1">20 &#x000b1; 1</td><td valign="top" align="center" rowspan="1" colspan="1">42 &#x000b1; 11</td><td valign="top" align="center" rowspan="1" colspan="1">71 &#x000b1; 4</td></tr><tr style="border-bottom: solid thin"><td valign="top" align="left" rowspan="1" colspan="1"><bold>Amount of CGM data per participant</bold> (days)</td><td valign="top" align="center" rowspan="1" colspan="1">89 (58, 119)</td><td valign="top" align="center" rowspan="1" colspan="1">91 (58, 124)</td><td valign="top" align="center" rowspan="1" colspan="1">90 (58, 124)</td><td valign="top" align="center" rowspan="1" colspan="1">80 (54, 109)</td><td valign="top" align="center" rowspan="1" colspan="1">77 (49, 106)</td><td valign="top" align="center" rowspan="1" colspan="1">90 (61, 120)</td><td valign="top" align="center" rowspan="1" colspan="1">95 (59, 122)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>CGM and closed-loop usage</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr style="border-bottom: solid thin"><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time using CGM and closed-loop (%)</td><td valign="top" align="center" rowspan="1" colspan="1">97 (93, 99)</td><td valign="top" align="center" rowspan="1" colspan="1">97 (94, 100)</td><td valign="top" align="center" rowspan="1" colspan="1">96 (92, 99)</td><td valign="top" align="center" rowspan="1" colspan="1">95 (89, 99)</td><td valign="top" align="center" rowspan="1" colspan="1">95 (90, 99)</td><td valign="top" align="center" rowspan="1" colspan="1">97 (93, 100)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (95, 100)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Boost usage</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Mean duration of Boost (min)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (43, 98)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (31, 68)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (32, 75)</td><td valign="top" align="center" rowspan="1" colspan="1">71 (48, 101)</td><td valign="top" align="center" rowspan="1" colspan="1">77 (51, 112)</td><td valign="top" align="center" rowspan="1" colspan="1">71 (49, 105)</td><td valign="top" align="center" rowspan="1" colspan="1">62 (40, 85)</td></tr><tr style="border-bottom: solid thin"><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Frequency of Boost use (per week)</td><td valign="top" align="center" rowspan="1" colspan="1">4.3 (1.8, 8.6)</td><td valign="top" align="center" rowspan="1" colspan="1">6.2 (3.1, 11.5)</td><td valign="top" align="center" rowspan="1" colspan="1">5.3 (2.4, 9.4)</td><td valign="top" align="center" rowspan="1" colspan="1">4.4 (1.9, 9.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3.6 (1.4, 8.0)</td><td valign="top" align="center" rowspan="1" colspan="1">3.8 (1.6, 7.8)</td><td valign="top" align="center" rowspan="1" colspan="1">4.4 (2.0, 8.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Ease-off usage</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Mean duration of Ease-off (min)</td><td valign="top" align="center" rowspan="1" colspan="1">82 (56, 120)</td><td valign="top" align="center" rowspan="1" colspan="1">64 (42, 99)</td><td valign="top" align="center" rowspan="1" colspan="1">73 (50, 114)</td><td valign="top" align="center" rowspan="1" colspan="1">84 (52, 130)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (62, 143)</td><td valign="top" align="center" rowspan="1" colspan="1">85 (60, 125)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (53, 101)</td></tr><tr style="border-bottom: solid thin"><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Frequency of Ease-off use (per week)</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 (1.0, 5.4)</td><td valign="top" align="center" rowspan="1" colspan="1">3.2 (1.4, 8.5)</td><td valign="top" align="center" rowspan="1" colspan="1">2.2 (1.0, 5.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9 (0.9, 4.2)</td><td valign="top" align="center" rowspan="1" colspan="1">2.7 (1.0, 5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 (1.0, 5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 (1.2, 5.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Sensor glucose: Boost on</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Glucose at start of Boost</td><td valign="top" align="center" rowspan="1" colspan="1">229 &#x000b1; 51</td><td valign="top" align="center" rowspan="1" colspan="1">245 &#x000b1; 51</td><td valign="top" align="center" rowspan="1" colspan="1">246 &#x000b1; 51</td><td valign="top" align="center" rowspan="1" colspan="1">242 &#x000b1; 58</td><td valign="top" align="center" rowspan="1" colspan="1">246 &#x000b1; 56</td><td valign="top" align="center" rowspan="1" colspan="1">221 &#x000b1; 47</td><td valign="top" align="center" rowspan="1" colspan="1">209 &#x000b1; 41</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Mean glucose (mg/dL)</td><td valign="top" align="center" rowspan="1" colspan="1">228 &#x000b1; 46</td><td valign="top" align="center" rowspan="1" colspan="1">248 &#x000b1; 46</td><td valign="top" align="center" rowspan="1" colspan="1">245 &#x000b1; 47</td><td valign="top" align="center" rowspan="1" colspan="1">234 &#x000b1; 49</td><td valign="top" align="center" rowspan="1" colspan="1">238 &#x000b1; 46</td><td valign="top" align="center" rowspan="1" colspan="1">220 &#x000b1; 44</td><td valign="top" align="center" rowspan="1" colspan="1">214 &#x000b1; 39</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time in range (%)</td><td valign="top" align="center" rowspan="1" colspan="1">28 &#x000b1; 22</td><td valign="top" align="center" rowspan="1" colspan="1">19 &#x000b1; 18</td><td valign="top" align="center" rowspan="1" colspan="1">21 &#x000b1; 19</td><td valign="top" align="center" rowspan="1" colspan="1">26 &#x000b1; 20</td><td valign="top" align="center" rowspan="1" colspan="1">25 &#x000b1; 19</td><td valign="top" align="center" rowspan="1" colspan="1">31 &#x000b1; 23</td><td valign="top" align="center" rowspan="1" colspan="1">31 &#x000b1; 23</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003c;70mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.0 (0.0, 0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.0 (0.0, 0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.0 (0.0, 0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.1 (0.0, 0.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.0 (0.0, 0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.0 (0.0, 0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.0 (0.0, 0.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003c;54mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0.00, 0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0.00, 0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0.00, 0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0.00, 0.10)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0.00, 0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0.00, 0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0.00, 0.00)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003e;180mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">72 &#x000b1; 22</td><td valign="top" align="center" rowspan="1" colspan="1">81 &#x000b1; 18</td><td valign="top" align="center" rowspan="1" colspan="1">79 &#x000b1; 19</td><td valign="top" align="center" rowspan="1" colspan="1">73 &#x000b1; 21</td><td valign="top" align="center" rowspan="1" colspan="1">75 &#x000b1; 20</td><td valign="top" align="center" rowspan="1" colspan="1">69 &#x000b1; 23</td><td valign="top" align="center" rowspan="1" colspan="1">68 &#x000b1; 23</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003e;250mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (14, 54)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (27, 68)</td><td valign="top" align="center" rowspan="1" colspan="1">46 (24, 67)</td><td valign="top" align="center" rowspan="1" colspan="1">36 (18, 59)</td><td valign="top" align="center" rowspan="1" colspan="1">41 (22, 60)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (12, 46)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (9, 38)</td></tr><tr style="border-top: solid thin"><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Sensor glucose: Ease-off on</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Glucose at start of Ease-off</td><td valign="top" align="center" rowspan="1" colspan="1">114 &#x000b1; 29</td><td valign="top" align="center" rowspan="1" colspan="1">118 &#x000b1; 32</td><td valign="top" align="center" rowspan="1" colspan="1">113 &#x000b1; 28</td><td valign="top" align="center" rowspan="1" colspan="1">108 &#x000b1; 33</td><td valign="top" align="center" rowspan="1" colspan="1">115 &#x000b1; 31</td><td valign="top" align="center" rowspan="1" colspan="1">114 &#x000b1; 28</td><td valign="top" align="center" rowspan="1" colspan="1">109 &#x000b1; 28</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Mean glucose (mg/dL)</td><td valign="top" align="center" rowspan="1" colspan="1">127 &#x000b1; 27</td><td valign="top" align="center" rowspan="1" colspan="1">124 &#x000b1; 25</td><td valign="top" align="center" rowspan="1" colspan="1">127 &#x000b1; 26</td><td valign="top" align="center" rowspan="1" colspan="1">125 &#x000b1; 29</td><td valign="top" align="center" rowspan="1" colspan="1">134 &#x000b1; 32</td><td valign="top" align="center" rowspan="1" colspan="1">127 &#x000b1; 27</td><td valign="top" align="center" rowspan="1" colspan="1">120 &#x000b1; 25</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time in range 70 to 180mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">75 &#x000b1; 14</td><td valign="top" align="center" rowspan="1" colspan="1">74 &#x000b1; 13</td><td valign="top" align="center" rowspan="1" colspan="1">74 &#x000b1; 13</td><td valign="top" align="center" rowspan="1" colspan="1">71 &#x000b1; 14</td><td valign="top" align="center" rowspan="1" colspan="1">71 &#x000b1; 15</td><td valign="top" align="center" rowspan="1" colspan="1">75 &#x000b1; 14</td><td valign="top" align="center" rowspan="1" colspan="1">80 &#x000b1; 12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003c;70mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">7.0 (2.9, 14.4)</td><td valign="top" align="center" rowspan="1" colspan="1">8.9 (4.4, 16.7)</td><td valign="top" align="center" rowspan="1" colspan="1">7.5 (3.4, 15.9)</td><td valign="top" align="center" rowspan="1" colspan="1">9.9 (3.6, 18.8)</td><td valign="top" align="center" rowspan="1" colspan="1">6.1 (2.5, 12.9)</td><td valign="top" align="center" rowspan="1" colspan="1">6.5 (2.5, 13.1)</td><td valign="top" align="center" rowspan="1" colspan="1">6.6 (2.7, 14.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003c;54mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.94 (0.00, 3.03)</td><td valign="top" align="center" rowspan="1" colspan="1">1.74 (0.44, 4.04)</td><td valign="top" align="center" rowspan="1" colspan="1">1.27 (0.17, 3.44)</td><td valign="top" align="center" rowspan="1" colspan="1">1.84 (0.24, 5.44)</td><td valign="top" align="center" rowspan="1" colspan="1">0.85 (0.00, 2.82)</td><td valign="top" align="center" rowspan="1" colspan="1">0.76 (0.00, 2.57)</td><td valign="top" align="center" rowspan="1" colspan="1">0.74 (0.00, 2.18)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003e;180mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 &#x000b1; 14</td><td valign="top" align="center" rowspan="1" colspan="1">14 &#x000b1; 13</td><td valign="top" align="center" rowspan="1" colspan="1">15 &#x000b1; 13</td><td valign="top" align="center" rowspan="1" colspan="1">15 &#x000b1; 15</td><td valign="top" align="center" rowspan="1" colspan="1">19 &#x000b1; 17</td><td valign="top" align="center" rowspan="1" colspan="1">15 &#x000b1; 14</td><td valign="top" align="center" rowspan="1" colspan="1">10 &#x000b1; 12</td></tr><tr style="border-top: solid thin"><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Sensor glucose: Neither on</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Mean glucose (mg/dL)</td><td valign="top" align="center" rowspan="1" colspan="1">151 &#x000b1; 20</td><td valign="top" align="center" rowspan="1" colspan="1">157 &#x000b1; 20</td><td valign="top" align="center" rowspan="1" colspan="1">151 &#x000b1; 19</td><td valign="top" align="center" rowspan="1" colspan="1">151 &#x000b1; 21</td><td valign="top" align="center" rowspan="1" colspan="1">160 &#x000b1; 24</td><td valign="top" align="center" rowspan="1" colspan="1">149 &#x000b1; 20</td><td valign="top" align="center" rowspan="1" colspan="1">144 &#x000b1; 16</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time in range 70 to 180mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">73 &#x000b1; 12</td><td valign="top" align="center" rowspan="1" colspan="1">66 &#x000b1; 11</td><td valign="top" align="center" rowspan="1" colspan="1">72 &#x000b1; 11</td><td valign="top" align="center" rowspan="1" colspan="1">73 &#x000b1; 12</td><td valign="top" align="center" rowspan="1" colspan="1">67 &#x000b1; 13</td><td valign="top" align="center" rowspan="1" colspan="1">74 &#x000b1; 12</td><td valign="top" align="center" rowspan="1" colspan="1">79 &#x000b1; 10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003c;70mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">2.1 (1.2, 3.4)</td><td valign="top" align="center" rowspan="1" colspan="1">3.3 (2.1, 4.8)</td><td valign="top" align="center" rowspan="1" colspan="1">2.7 (1.8, 4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 (1.5, 3.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9 (1.1, 3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9 (1.1, 3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.4 (0.7, 2.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003c;54mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.33 (0.15, 0.66)</td><td valign="top" align="center" rowspan="1" colspan="1">0.60 (0.31, 1.09)</td><td valign="top" align="center" rowspan="1" colspan="1">0.48 (0.24, 0.82)</td><td valign="top" align="center" rowspan="1" colspan="1">0.41 (0.20, 0.73)</td><td valign="top" align="center" rowspan="1" colspan="1">0.32 (0.16, 0.62)</td><td valign="top" align="center" rowspan="1" colspan="1">0.28 (0.12, 0.57)</td><td valign="top" align="center" rowspan="1" colspan="1">0.14 (0.06, 0.34)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003e;180mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">25 &#x000b1; 12</td><td valign="top" align="center" rowspan="1" colspan="1">30 &#x000b1; 12</td><td valign="top" align="center" rowspan="1" colspan="1">25 &#x000b1; 11</td><td valign="top" align="center" rowspan="1" colspan="1">25 &#x000b1; 12</td><td valign="top" align="center" rowspan="1" colspan="1">30 &#x000b1; 14</td><td valign="top" align="center" rowspan="1" colspan="1">24 &#x000b1; 12</td><td valign="top" align="center" rowspan="1" colspan="1">19 &#x000b1; 11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Time &#x0003e;250mg/dL (%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (2, 9)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (4, 12)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (3, 10)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (2, 12)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (4, 14)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2, 8)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1, 5)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p id="P28">Data are presented as mean (standard deviation) or median (IQR)</p></fn></table-wrap-foot></table-wrap></floats-group></article>